drugset / Trial / NCT04985955

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3

NCT04985955

Phase 1 Completed 12 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.

Timeline

Start
2021-07-30
Primary completion
2021-09-21
Completion
2021-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule Oral

Indications

No indication recorded.